Skip to main content
. Author manuscript; available in PMC: 2016 Jan 31.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2014 Dec 3;24(2):435–441. doi: 10.1158/1055-9965.EPI-14-1178

Figure 1.

Figure 1

Performance of CA-125 (MUC16) in discriminating invasive cancers from benign controls in the breast cancer reference set. A) ROC curves showing the training and validation data for estrogen receptor positive cancers based on CA-125 levels. The comparison is invasive cancers versus benign breast conditions without atypia. B) ROC curves showing the training and validation data for estrogen receptor negative cancers based on CA-125 levels. The comparison is invasive cancers versus benign breast conditions without atypia.